Molecular genetic profile of seromucinous ovarian tumors

Close metadata

Seromucinous tumors belong to a group of ovarian epithelial tumors. They were originally described as tumors characterized by Müllerian endocervical differentiation. Molecular genetic studies have indicated these tumors as endometriosis-associated tumors due to the presence of ARID1 gene mutations. However, the histogenesis of these neoplasms is still unstudied.

Keywords:

ovarian epithelial tumors

endometriosis-associated ovarian tumors

histogenesis of ovarian tumors

Authors:

Novikov F.V.

Kursk State Medical University of the Ministry of Health of Russia

Luneva I.S.

Kursk State Medical University of the Ministry of Health of Russia

Starkova O.A.

Kursk State Medical University of the Ministry of Health of Russia

Received:

18.08.2020

Accepted:

16.11.2020

List of references:

Kurman R. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014.
Fox H, Langley FA. Tumors of the ovary. Chicago: William Heinemann/Year Book; 1976.
Rutgers JL, Scully RE. Rutgers J, Scully R. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer. 1988;61(2):340-348. https://doi.org/10.1002/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U "> 3.0.CO;2-U" target="_blank">https://doi.org/10.1002/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U
Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type. A clinicopathologic analysis. Cancer. 1988;61(3):546-554. https://doi.org/10.1002/1097-0142(19880201)61:3<546::AID-CNCR2820610321>3.0.CO;2-I "> 3.0.CO;2-I" target="_blank">https://doi.org/10.1002/1097-0142(19880201)61:3<546::AID-CNCR2820610321>3.0.CO;2-I
Tavassoli F, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: WHO; 2003.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26(12):1529-1541. https://doi.org/10.1097/00000478-200212000-00001
Kurman RJ, Shih IeM. Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol. 2016;35(1):78-81. https://doi.org/10.1097/pgp.0000000000000266
Nagamine M, Mikami Y. Ovarian seromucinous tumors: pathogenesis, morphologic spectrum, and clinical issues. Diagnostics (Basel). 2020;10(2):77.
Rutgers JKL. Mullerian mucinous/mixed epithelial (seromucinous) ovarian tumors. AJSP: Reviews & Reports. 2016;21(5):206-213.
Munjishvili V, Barabadze E, Musashvili T, Gachechiladze M, Burkadze G. Morphophenotypic characteristics of ovarian serous borderline tumors. Georgian Med News. 2019;290:20-25.
Mills AM, Shanes ED. Mucinous ovarian tumors. Surg Pathol Clin. 2019;12(2):565-585. https://doi.org/10.1016/j.path.2019.01.008
Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125-142. https://doi.org/10.1007/s00428-016-2040-8
Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25(1):83-89. https://doi.org/10.1097/01.pgp.0000177125.31046.fd
Yasunaga M, Ohishi Y, Oda Y, Misumi M, Iwasa A, Kurihara S, Nishimura I, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol. 2009;40(7): 965-974. https://doi.org/10.1016/j.humpath.2008.12.006
Hamada T, Kiyokawa T, Nomura K, Hano H. Immunohistochemical analysis of reserve cell-like cells of ovarian müllerian mucinous/mixed epithelial borderline tumor. Int J Gynecol Pathol. 2008;27(2):199-206. https://doi.org/10.1097/pgp.0b013e31815b077b
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol. 2012;31(4):297-303. https://doi.org/10.1097/pgp.0b013e31823f8482
Wilsker D, Probst L, Wain HM, Maltais L, Tucker PW, Moran E. Nomenclature of the ARID family of DNA-binding proteins. Genomics. 2005;86(2):242-251. https://doi.org/10.1016/j.ygeno.2005.03.013
Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718-6727. [published correction appears in Cancer Res. 2012;72(12):3116]. https://doi.org/10.1158/0008-5472.can-11-1562
Maeda D, Shih IeM. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013;20(1):45-52. https://doi.org/10.1097/pap.0b013e31827bc24d
Ding XH, Tian X, Wang LQ, Wang Y, Liu AJ. Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance. Zhonghua Bing Li Xue Za Zhi. 2020;49(6):588-593. https://doi.org/10.3760/cma.j.cn112151-20200224-00130
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-1543. https://doi.org/10.1056/NEJMoa1008433
Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-231. https://doi.org/10.1126/science.1196333
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22(8):1310-1315. https://doi.org/10.1097/IGC.0b013e31826b5dcc
Levakov SA, Gromova T, Kedrova AG, Sheshukova NA. Endometriosis-associated ovarian cancer. Opukholi zhenskoi reproduktivnoi sistemy/Tumors of Female Reproductive System. 2016;12(4):47-51. (In Russ.). https://doi.org/10.17650/1994-4098-2016-12-4-47-51
Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733-747. https://doi.org/10.1016/j.ajpath.2015.11.011
Kim KR, Choi J, Hwang JE, Baik YA, Shim JY, Kim YM, Robboy SJ. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology. 2010;57(4):587-596. https://doi.org/10.1111/j.1365-2559.2010.03673.x
Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4(2):111-120. https://doi.org/10.1016/s1535-6108(03)00191-0
Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052-7056.
Wu RC, Chen SJ, Chen HC, Tan KT, Jung SM, Lin CY, Chao AS, Huang KG, Chou HH, Chang TC, Chao A, Lai CH. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor. Mod Pathol. Jul 2 2020. https://doi.org/10.1038/s41379-020-0611-3
Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, Morris D, Duggan MA, McCluggage WG, Köbel M. Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol. 2017;41(5):685-695. https://doi.org/10.1097/PAS.0000000000000812
Ng A, Barker N. Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol. 2015;16(10):625-638. https://doi.org/10.1038/nrm4056
Karpathiou G, Chauleur C, Corsini T, Venet M, Habougit C, Honeyman F, Forest F, Peoc’h M. Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors. Ann Diagn Pathol. 2017;27:28-33. https://doi.org/10.1016/j.anndiagpath.2017.01.002
Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer — shifting the paradigm. Hum Pathol. 2011;42(7):918-931. https://doi.org/10.1016/j.humpath.2011.03.003
Novikov FV, Luneva IS, Mishina ES, Mnikhovich MV. Morphological basics of ovarian tumor histogenesis. Opukholi zhenskoi reproduktivnoi sistemy/Tumors of Female Reproductive System. 2020; 16(1):78-84. (In Russ.). https://doi.org/10.17650/1994-4098-2020-16-1-78-84
Karpathiou G, Chauleur C, Venet M, Clemenson A, Peoc’h M. Pathology of the fallopian tube: tubal involvement by ovarian tumors and incidental findings in the nontumoral setting. Pathobiology. 2020;87(1):37-44. https://doi.org/10.1159/000505406
Ershov VA, Mikhailov VM, Chirsky VS. Reserve and basal cells of the cervical epithelium as a source of cervical neoplasia associated with human papilloma viruses. Genes & Cells. 2019;14(1):80-84. (In Russ.). https://doi.org/10.23868/201903011

Close metadata